Trinity Biotech plc announced that it has received the final regulatory clearance to begin upstream manufacturing of its WHO‑prequalified Uni‑Gold HIV rapid test under an offshored and outsourced production model. The approval, granted by the in‑country health product regulator on February 10, 2026, removes the last regulatory hurdle in the company’s comprehensive transformation plan for the Uni‑Gold line.
The clearance allows Trinity to move upstream production activities to a lower‑cost, highly scalable offshore partner. Management estimates the shift will be gross‑margin accretive, improve working‑capital efficiency, and free up capital that can be deployed to fund the high‑risk continuous glucose monitoring (CGM) platform. The move is expected to reduce fixed manufacturing costs and increase the company’s ability to meet growing demand for WHO‑prequalified HIV tests in emerging markets.
Trinity’s broader transformation strategy has focused on consolidating U.S. manufacturing sites, cutting fixed costs, and generating cash flow to support its CGM development. The company’s debt burden of $117.2 million and recent negative EBITDA underscore the importance of this cost‑saving measure. By shifting production offshore, Trinity aims to improve its financial position and move closer to the target of positive adjusted EBITDA in the second quarter of 2025.
The announcement triggered a strong market reaction: the stock rose 17.5% to $0.94, reflecting investor confidence that the regulatory approval will deliver the promised margin expansion and working‑capital benefits. Analysts highlighted the approval as a key milestone in the company’s turnaround plan.
President and CEO John Gillard said, “This approval is a critical final milestone in the execution of our Comprehensive Transformation Plan. Combined with our prior WHO authorization, Trinity now has the regulatory approvals to fully realise the potential of this outsourced and offshored manufacturing model for Uni‑Gold HIV.”
The Uni‑Gold test’s WHO pre‑qualification is essential for use in global health programs, and the new approval positions Trinity to capture a larger share of the rapidly expanding HIV testing market in low‑ and middle‑income countries. The company’s ability to scale production offshore is expected to support higher volumes and lower unit costs, thereby enhancing revenue growth potential.
While the approval marks a significant step forward, Trinity still faces challenges, including a substantial debt load and the need to achieve positive adjusted EBITDA. The company’s management remains focused on disciplined cost management and strategic investment in its CGM platform to sustain long‑term growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.